Related Experiment Video
Updated: Aug 18, 2025

06:09
An In Ovo Model for Testing Insulin-mimetic Compounds
Published on: April 23, 2018
10.7K
Bench-Side Dose Accuracy of an Open-Source Ultra-Low-Cost Insulin-Pump, With Testing Conducted to IEC 60601-2-24
Matthew Payne1, Francis Pooke1, Lui Holder-Pearson1,2
1Centre for Bio-engineering, Department of Mechanical Engineering, University of Canterbury, Christchurch, New Zealand.
Journal of Diabetes Science and Technology
|December 8, 2022
Summary
An ultra-low-cost insulin pump, built for under $100, demonstrates comparable accuracy to commercial pumps. This innovation could improve diabetes management and reduce healthcare costs, addressing health disparities.
Area of Science:
- Biomedical Engineering
- Medical Devices
- Diabetes Technology
Background:
- Rising global diabetes prevalence necessitates cost-effective management solutions.
- Significant treatment and indirect costs associated with diabetes impact individuals and healthcare systems.
- Health disparities in diabetes care highlight the need for accessible technologies.
Purpose of the Study:
- To present test results for an ultra-low-cost insulin pump prototype.
- To evaluate the accuracy and performance of a low-cost insulin pump against established standards.
- To assess the potential of affordable insulin pumps in improving diabetes care accessibility.
Main Methods:
- Development of an insulin pump using components with a bill of materials under $US100.
- Bench testing conducted in accordance with IEC60601-2-24 standards.
- Performance benchmarking against a commercially available insulin pump.
Main Results:
- The ultra-low-cost insulin pump achieved comparable accuracy to a commercial pump.
- Testing revealed an overall accuracy of 0.089% for the prototype pump.
- The prototype pump demonstrated a -0.392% accuracy in specific tests.
- Limited bench testing indicates accurate insulin delivery capabilities.
Conclusions:
- An ultra-low-cost insulin pump can accurately deliver insulin, showing promise for broader accessibility.
- Further testing in diverse environments is necessary to meet full IEC60601-2-24 compliance.
- This technology has the potential to mitigate health disparities in diabetes management.
Related Concept Videos
Insulin: Dosing Regimen and Adverse Effects
226
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
226
Insulin Formulations: Types and Delivery
250
Insulin preparations are categorized by their duration of action into short-acting and long-acting types. Two strategies are used to modify insulin's absorption and pharmacokinetic profile: slowing the absorption post-subcutaneous injection, or altering human insulin's amino acid sequence or protein structure. These changes retain the insulin's ability to bind to the insulin receptor, but alter its behavior in solution or after injection.
Short-acting insulins are divided into...
Short-acting insulins are divided into...
250

